The RhoGEF GEF-H1 Is Required for Oncogenic RAS Signaling via KSR-1

Cancer Cell

Volumn 25, Issue 2, 2014, Pages 181-195

  Cullis, Jane ^a,b   Meiri, David ^a   Sandi, MariaJose ^a   Radulovich, Nikolina ^a,b   Kent, OliverA ^a   Medrano, Mauricio ^a,b   Mokady, Daphna ^a   Normand, Josee ^a   Larose, Jose ^a   Marcotte, Richard ^a   Marshall, ChristopherB ^a   Ikura, Mitsuhiko ^a,b   Ketela, Troy ^b   Moffat, Jason ^b   Neel, BenjaminG ^a,b   Gingras, Anne Claude ^b,d   Tsao, Ming Sound ^a,b   Rottapel, Robert ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR GEF H1; SCAFFOLD PROTEIN; SCAFFOLD PROTEIN KSR1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA CHAIN; CANCER CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; GENE; GENE ARHGEF2; HUMAN; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ONCOGENE H RAS; ONCOGENE RAS; PANCREAS TUMOR; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; NIH 3T3 CELLS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASES; RAS PROTEINS; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84893610509     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.01.025     Document Type: Article

References (63)

1. Al-Aynati M.M., Radulovich N., Riddell R.H., Tsao M.S. Epithelial-cadherin and beta-catenin expression changes in pancreatic intraepithelial neoplasia. Clin. Cancer Res. 2004, 10:1235-1240.
2. Birukova A.A., Birukov K.G., Gorshkov B., Liu F., Garcia J.G., Verin A.D. MAP kinases in lung endothelial permeability induced by microtubule disassembly. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L75-L84.
3. Brecht M., Steenvoorden A.C., Collard J.G., Luf S., Erz D., Bartram C.R., Janssen J.W. Activation of gef-h1, a guanine nucleotide exchange factor for RhoA, by DNA transfection. Int. J. Cancer 2005, 113:533-540.
4. Buday L., Warne P.H., Downward J. Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos. Oncogene 1995, 11:1327-1331.
5. Cacace A.M., Michaud N.R., Therrien M., Mathes K., Copeland T., Rubin G.M., Morrison D.K. Identification of constitutive and ras-inducible phosphorylation sites of KSR: implications for 14-3-3 binding, mitogen-activated protein kinase binding, and KSR overexpression. Mol. Cell. Biol. 1999, 19:229-240.
6. Chen J.C., Zhuang S., Nguyen T.H., Boss G.R., Pilz R.B. Oncogenic Ras leads to Rho activation by activating the mitogen-activated protein kinase pathway and decreasing Rho-GTPase-activating protein activity. J.Biol. Chem. 2003, 278:2807-2818.
7. Cheng I.K., Tsang B.C., Lai K.P., Ching A.K., Chan A.W., To K.F., Lai P.B., Wong N. GEF-H1 over-expression in hepatocellular carcinoma promotes cell motility via activation of RhoA signalling. J.Pathol. 2012, 228:575-585.
8. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
9. Dougherty M.K., Müller J., Ritt D.A., Zhou M., Zhou X.Z., Copeland T.D., Conrads T.P., Veenstra T.D., Lu K.P., Morrison D.K. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 2005, 17:215-224.
10. Engers R., Zwaka T.P., Gohr L., Weber A., Gerharz C.D., Gabbert H.E. Tiam1 mutations in human renal-cell carcinomas. Int. J. Cancer 2000, 88:369-376.
11. Estep A.L., Palmer C., McCormick F., Rauen K.A. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS ONE 2007, 2:e1279.
12. Frolov A., Chahwan S., Ochs M., Arnoletti J.P., Pan Z.Z., Favorova O., Fletcher J., von Mehren M., Eisenberg B., Godwin A.K. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol. Cancer Ther. 2003, 2:699-709.
13. Fujishiro S.H., Tanimura S., Mure S., Kashimoto Y., Watanabe K., Kohno M. ERK1/2 phosphorylate GEF-H1 to enhance its guanine nucleotide exchange activity toward RhoA. Biochem. Biophys. Res. Commun. 2008, 368:162-167.
14. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
15. Guo X., Zhang X., Li Y., Guo Y., Wang J., Li Y., Shen B., Sun D., Zhang J. Nocodazole increases the ERK activity to enhance MKP-1expression which inhibits p38 activation induced by TNF-α. Mol. Cell. Biochem. 2012, 364:373-380.
16. Gupta S., Ramjaun A.R., Haiko P., Wang Y., Warne P.H., Nicke B., Nye E., Stamp G., Alitalo K., Downward J. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007, 129:957-968.
17. Harrison R.E., Turley E.A. Active erk regulates microtubule stability in H-ras-transformed cells. Neoplasia 2001, 3:385-394.
18. Hayne C., Tzivion G., Luo Z. Raf-1/MEK/MAPK pathway is necessary for the G2/M transition induced by nocodazole. J.Biol. Chem. 2000, 275:31876-31882.
19. Heisermann G.J., Wiley H.S., Walsh B.J., Ingraham H.A., Fiol C.J., Gill G.N. Mutational removal of the Thr669 and Ser671 phosphorylation sites alters substrate specificity and ligand-induced internalization of the epidermal growth factor receptor. J.Biol. Chem. 1990, 265:12820-12827.
20. Jacobs D., Glossip D., Xing H., Muslin A.J., Kornfeld K. Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. Genes Dev. 1999, 13:163-175.
21. Janssens V., Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 2001, 353:417-439.
22. Kirkman, T.W. (2006). Statistics to use. http://www.physics.csbsju.edu/stats.
23. Lambert J.M., Lambert Q.T., Reuther G.W., Malliri A., Siderovski D.P., Sondek J., Collard J.G., Der C.J. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat. Cell Biol. 2002, 4:621-625.
24. Li X., Huang Y., Jiang J., Frank S.J. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell. Signal. 2008, 20:2145-2155.
25. Liao Y.C., Ruan J.W., Lua I., Li M.H., Chen W.L., Wang J.R., Kao R.H., Chen J.H. Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling. Oncogene 2012, 31:3086-3097.
26. Lozano J., Xing R., Cai Z., Jensen H.L., Trempus C., Mark W., Cannon R., Kolesnick R. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. Cancer Res. 2003, 63:4232-4238.
27. Macara I.G., Lounsbury K.M., Richards S.A., McKiernan C., Bar-Sagi D. The Ras superfamily of GTPases. FASEB J. 1996, 10:625-630.
28. Malliri A., van der Kammen R.A., Clark K., van der Valk M., Michiels F., Collard J.G. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 2002, 417:867-871.
29. Marcotte R., Brown K.R., Suarez F., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L., et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov 2012, 2:172-189.
30. Meiri D., Marshall C.B., Greeve M.A., Kim B., Balan M., Suarez F., Bakal C., Wu C., Larose J., Fine N., et al. Mechanistic insight into the microtubule and actin cytoskeleton coupling through dynein-dependent RhoGEF inhibition. Mol. Cell 2012, 45:642-655.
31. Michaud N.R., Therrien M., Cacace A., Edsall L.C., Spiegel S., Rubin G.M., Morrison D.K. KSR stimulates Raf-1 activity in a kinase-independent manner. Proc. Natl. Acad. Sci. USA 1997, 94:12792-12796.
32. Mizuarai S., Yamanaka K., Kotani H. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res. 2006, 66:6319-6326.
33. Moodie S.A., Willumsen B.M., Weber M.J., Wolfman A. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993, 260:1658-1661.
34. Morrison D.K. KSR: a MAPK scaffold of the Ras pathway?. J.Cell Sci. 2001, 114:1609-1612.
35. Mulcahy H.E., Lyautey J., Lederrey C., qi Chen X., Anker P., Alstead E.M., Ballinger A., Farthing M.J., Stroun M. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin. Cancer Res. 1998, 4:271-275.
36. Nguyen A., Burack W.R., Stock J.L., Kortum R., Chaika O.V., Afkarian M., Muller W.J., Murphy K.M., Morrison D.K., Lewis R.E., et al. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation invivo. Mol. Cell. Biol. 2002, 22:3035-3045.
37. Oliveira C., Velho S., Moutinho C., Ferreira A., Preto A., Domingo E., Capelinha A.F., Duval A., Hamelin R., Machado J.C., et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007, 26:158-163.
38. Ory S., Zhou M., Conrads T.P., Veenstra T.D., Morrison D.K. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr. Biol. 2003, 13:1356-1364.
39. Owens D.M., Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007, 26:3203-3213.
40. Philp A.J., Campbell I.G., Leet C., Vincan E., Rockman S.P., Whitehead R.H., Thomas R.J., Phillips W.A. The phosphatidylinositol 3'-kinasep85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001, 61:7426-7429.
41. Porfiri E., McCormick F. Regulation of epidermal growth factor receptor signaling by phosphorylation of the ras exchange factor hSOS1. J.Biol. Chem. 1996, 271:5871-5877.
42. Prendergast G.C., Khosravi-Far R., Solski P.A., Kurzawa H., Lebowitz P.F., Der C.J. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 1995, 10:2289-2296.
43. Qiu R.G., Chen J., Kirn D., McCormick F., Symons M. An essential role for Rac in Ras transformation. Nature 1995, 374:457-459.
44. Razidlo G.L., Kortum R.L., Haferbier J.L., Lewis R.E. Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation. J.Biol. Chem. 2004, 279:47808-47814.
45. Ren Y., Li R., Zheng Y., Busch H. Cloning and characterization of GEF-H1, a microtubule-associated guanine nucleotide exchange factor for Rac and Rho GTPases. J.Biol. Chem. 1998, 273:34954-34960.
46. Ritt D.A., Monson D.M., Specht S.I., Morrison D.K. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell. Biol. 2010, 30:806-819.
47. Sahai E., Olson M.F., Marshall C.J. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J. 2001, 20:755-766.
48. Samuels Y., Velculescu V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004, 3:1221-1224.
49. Sandelin A., Wasserman W.W., Lenhard B. ConSite: web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res. 2004, 32:W249-W252.
50. Sieburth D.S., Sundaram M., Howard R.M., Han M. A PP2A regulatory subunit positively regulates Ras-mediated signaling during Caenorhabditis elegans vulval induction. Genes Dev. 1999, 13:2562-2569.
51. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
52. Smit V.T., Boot A.J., Smits A.M., Fleuren G.J., Cornelisse C.J., Bos J.L. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988, 16:7773-7782.
53. Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K., Davis R.J., Scott J.D. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Nat. Cell Biol. 2010, 12:1242-1249.
54. Sundaram M., Han M. The C. elegans ksr-1 gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. Cell 1995, 83:889-901.
55. Therrien M., Chang H.C., Solomon N.M., Karim F.D., Wassarman D.A., Rubin G.M. KSR, a novel protein kinase required for RAS signal transduction. Cell 1995, 83:879-888.
56. Therrien M., Michaud N.R., Rubin G.M., Morrison D.K. KSR modulates signal propagation within the MAPK cascade. Genes Dev. 1996, 10:2684-2695.
57. Vojtek A.B., Hollenberg S.M., Cooper J.A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 1993, 74:205-214.
58. Warne P.H., Viciana P.R., Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 invitro. Nature 1993, 364:352-355.
59. Wassarman D.A., Solomon N.M., Chang H.C., Karim F.D., Therrien M., Rubin G.M. Protein phosphatase 2A positively and negatively regulates Ras1-mediated photoreceptor development in Drosophila. Genes Dev. 1996, 10:272-278.
60. Whitehead I., Kirk H., Tognon C., Trigo-Gonzalez G., Kay R. Expression cloning of lfc, a novel oncogene with structural similarities to guanine nucleotide exchange factors and to the regulatory region of protein kinase C. J.Biol. Chem. 1995, 270:18388-18395.
61. Xiao H., Zhang Q., Shen J., Bindokas V., Xing H.R. Pharmacologic inactivation of kinase suppressor of Ras1 sensitizes epidermal growth factor receptor and oncogenic Ras-dependent tumors to ionizing radiation treatment. Mol. Cancer Ther. 2010, 9:2724-2736.
62. Zhang Z., Gerstein M. Of mice and men: phylogenetic footprinting aids the discovery of regulatory elements. J.Biol. 2003, 2:11.
63. Zhang X.F., Settleman J., Kyriakis J.M., Takeuchi-Suzuki E., Elledge S.J., Marshall M.S., Bruder J.T., Rapp U.R., Avruch J. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 1993, 364:308-313.